小智港股覆盤 | 4月13日
今日，港股三大指數集體上漲。截止收盤，恆生指數漲0.26%，報21374點。國企指數漲0.69%，報7314點。恆生科技指數漲0.45%，報4268點。市場約802只個股上漲，811只個股下跌。成交額突破1002.09億港幣，和昨天同期相比下跌21.93%。南下資金淨流入29.25億港幣。
盤面上，有色金屬和鋼鐵板塊集體拉昇。MONGOL MINING漲超21%；招金礦業漲超11%；紫金礦業漲超8%；洛陽鉬業、中國有色礦業等多股漲超7%。MONGOL MINING因購股權獲行使發行497.4萬股；招金礦業將於4月25日舉行董事會會議以審批一季度業績；中金升紫金目標價至17.8元，單季利潤創新高，或迎強勁增長；洛陽鉬業：2022年度第一期超短期融資券兌付完成；廣發證券：維持中國有色礦業“買入”評級，合理價值爲7.92港元。
石油天然氣板塊大漲靠前。蒙古能源漲超18%；中國秦發漲超11%；伊泰煤炭漲超10%；兗煤澳大利亞漲超8%；恆鼎實業漲超7%。恆鼎實業首三月原煤產量總計88.9萬噸，同比增長23%。
菸草板塊走高。思摩爾國際漲超2%。
食品零售板塊跌幅居前。高鑫零售、運興泰集團等多股跌超5%；麥迪森控股跌超3%；萬隆控股集團跌超2%；亨泰跌超1%。瑞銀下調高鑫零售目標價至3.02元，評級「中性」。
CRO板塊走低。金斯瑞生物科技跌超6%；奧星生命科技、昭衍新藥等多股跌超3%；康龍化成、泰格醫藥等多股跌超2%。中泰國際：重申昭衍新藥“買入”評級，目標價升至130.75港元。
生物科技板塊走弱。榮昌生物-B跌超10%；中國抗體-B跌超8%；康寧傑瑞製藥-B、科濟藥業-B等多股跌超6%；昊海生物科技跌超5%。大和下調榮昌生物目標價19.3%至92港元，料其2022年收入低於預期；康寧傑瑞製藥-B高開逾4%，於2022年AACR年會上發佈KN046聯合KN026治療HER2陽性實體瘤的最新臨牀數據；瑞銀下調科濟藥業-B目標價至38元，評級「買入」；昊海生物科技遭董事長減持1.8萬股A股。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
